Figure S1. Origin of thyroid samples used in our study
A: gene 3’expression microarray study; B: validation studies (exon microarray and qPCR)
A.
Microarray study
(gene 3’expression microarray)
150 aliquots of RNA from 108 young PTC patients
received from CTB
80 aliquots
PTC
70 aliquots
normal thyroid
15 discarded due to:
3x lack/low RNA
2x degraded RNA
1x bad quality of cRNA
3x technical outliers
6x biological outliers
19 discarded due to:
12x lack/low RNA
2x bad quality of cRNA
1x technical outliers
3x biological outliers
1x no tumor for comparison
Samples finally included into initial microarray study
65 PTC
microarray studies
18
PTC samples
only
51 normal thyroid
microarray studies
47
PTCs and normal thyroids
from the same
patients
4*
normal thyroid
samples only
* Their tumor counterparts were discarded (1x lack of RNA; 3x biological outliers)
B.
Validation studies
75 RNA aliquots from 75 young PTC patients
CTB
patients
27 PTC samples for QPCR
(all independent
from initial study)
25 PTC samples for exon microarray
(all but 1 previously included
in final analysis of initial 3’ expression
microarray study)
70 aliquots
Polish
PTC
normal
patientsthyroid
non-ECR only,
19 discarded due
17 PTC samples for QPCR
19 PTC samples for QPCR
born after to:
the catastrophe
12x lack/low RNA
2x bad quality of
21 PTC samples
6 PTC samples
cRNA
for exon microarray
for exon microarray
1x technical
outliners
3x biological
Samples included finally into validation study
outliners
1x no Tu for
36 PTC samples for QPCR validation
comprision
CTB samples included into
validation study
into validation study
27 PTC samples for exon microarray validation